An FDA advisory committee voted to recommend targeting three influenza strains in vaccines for use in the next flu season.
On the first day of a two-day meeting, the Vaccines and Related Biological Products Advisory Committee voted 14 to 0 to recommend two strains for the trivalent flu virus vaccine — which consists of three inactivated flu viruses — and a third strain for vaccines that protect again four strains of the virus.
The three strains are A/Brisbane/02/2018(H1N1)pdm09 and B/Colorado/06/2017 for the trivalent vaccine and B/Phuket/3073/2013 for quadrivalent vaccines. FDA presenters at the meeting noted that Influenza A(H1N1)pdm09 viruses are the most common nationwide.
